Companies / SpyGlass Pharma, Inc. / Activity
Activity — SpyGlass Pharma, Inc.
169 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Vensana Capital I GP, LLC 10% owner | Other | Common Stock | — | +548K +32.43% | 2,238,297 6.69% of shares | low |
| Feb 9, 2026 | Vensana Capital I GP, LLC 10% owner | Other | Common Stock | — | +1.7M | 1,690,230 5.05% of shares | low |
| Feb 5, 2026 | Khan Bilal Arshad Director | Grant | Stock Option (right to buy) | — | +14K | 13,700 0.04% of shares | low |
| Feb 5, 2026 | Pujara Chetan Pratap Executive | Grant | Stock Option (right to buy) | — | +105K | 105,000 0.31% of shares | low |
| Feb 5, 2026 | Dennewill James Robert Jr. Executive | Grant | Stock Option (right to buy) | — | +105K | 105,000 0.31% of shares | low |
| Feb 5, 2026 | Mooney Patrick H. CEO | Grant | Stock Option (right to buy) | — | +300K | 300,000 0.90% of shares | low |
| Feb 5, 2026 | Kahook Malik Y. Executive | Grant | Stock Option (right to buy) | — | +105K | 105,000 0.31% of shares | low |
| Feb 5, 2026 | Pardo Geoffrey B Director | Grant | Stock Option (right to buy) | — | +27K | 27,400 0.08% of shares | low |
| Feb 5, 2026 | O'Farrell Elizabeth G. Director | Grant | Stock Option (right to buy) | — | +14K | 13,700 0.04% of shares | low |
| Feb 5, 2026 | Dable Habib J Director | Grant | Stock Option (right to buy) | — | +27K | 27,400 0.08% of shares | low |
| Feb 5, 2026 | Dybbs Michael Director | Grant | Stock Option (right to buy) | — | +27K | 27,400 0.08% of shares | low |
| Feb 5, 2026 | Nielsen Kirk G. Director | Grant | Stock Option (right to buy) | — | +27K | 27,400 0.08% of shares | low |
| Feb 5, 2026 | Viret Jean-Frederic Executive | Grant | Stock Option (right to buy) | — | +18K | 17,500 0.05% of shares | low |
| Feb 5, 2026 | RA Capital Management, L.P. Director | Grant | Stock Option (right to buy) | — | +27K | 27,400 0.08% of shares | low |
| Feb 5, 2026 | Behbahani Ali Director | Grant | Stock Option (right to buy) | — | +27K | 27,400 0.08% of shares | low |
| Feb 9, 2026 | Nielsen Kirk G. Director | Other | Series D Preferred Stock | — | -359K -100.00% | 0 0.00% of shares | low |
| Feb 9, 2026 | Nielsen Kirk G. Director | Other | Series C-2 Preferred Stock | — | -548K -100.00% | 0 0.00% of shares | low |
| Feb 9, 2026 | Nielsen Kirk G. Director | Other | Series C-1 Preferred Stock | — | -548K -100.00% | 0 0.00% of shares | low |
| Feb 9, 2026 | Nielsen Kirk G. Director | Other | Series B Preferred Stock | — | -1.7M -100.00% | 0 0.00% of shares | low |